Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

(2020) Keenan T. Hartert et al.   LEUKEMIA

Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)

(2020) Xin Xu et al.   Cell Death & Disease

Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation

(2020) Andrés J. M. Ferreri et al.   HEMATOLOGICAL ONCOLOGY

Micheliolide Protects Against Doxorubicin-Induced Cardiotoxicity in Mice by Regulating PI3K/Akt/NF-kB Signaling Pathway

(2019) Ashkan Kalantary-Charvadeh et al.   Cardiovascular Toxicology

A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

(2019) Toby A. Eyre et al.   HEMATOLOGICAL ONCOLOGY

R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial

(2019) Andrea Kühnl et al.   ANNALS OF HEMATOLOGY

Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma

(2019) Fansheng Ran et al.   BIOORGANIC CHEMISTRY

High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

(2019) Sung-Won Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies

(2019) Pallawi Torka et al.   Current Hematologic Malignancy Reports

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma

(2019) Jennifer L. Crombie et al.   Surgical Oncology Clinics of North America

Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin’s lymphoma

(2018) Thomas D. Rodgers et al.   EXPERT OPINION ON EMERGING DRUGS

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib

(2018) Marina Danilenko et al.   JAMA Dermatology

Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk

(2018) Richard Caldwell et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

(2018) Sean D. Reiff et al.   Cancer Discovery

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

(2018) Yaya Chu et al.   OncoImmunology

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Clinical approach to diffuse large B cell lymphoma

(2016) Paolo F. Caimi et al.   BLOOD REVIEWS

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

(2016) Grzegorz S. Nowakowski et al.   JNCI-Journal of the National Cancer Institute

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

(2016) L M Saleh et al.   LEUKEMIA

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease

(2016) H van Andel et al.   ONCOGENE

CYLD Proteolysis Protects Macrophages from TNF-Mediated Auto-necroptosis Induced by LPS and Licensed by Type I IFN

(2016) Diana Legarda et al.   Cell Reports

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

(2016) Grzegorz S. Nowakowski et al.   JNCI-Journal of the National Cancer Institute

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) H. Tilly et al.   ANNALS OF ONCOLOGY

Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia

(2015) Mansi Arora et al.   BLOOD CELLS MOLECULES AND DISEASES

Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia

(2015) Mansi Arora et al.   PEDIATRIC BLOOD & CANCER

Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies

(2015) BING XIA et al.   Oncology Letters

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

(2015) Scott A. Ezell et al.   Oncotarget

Clinical significance of CYLD downregulation in breast cancer

(2014) Mitsuhiro Hayashi et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies

(2014) Maike Buchner et al.   CURRENT OPINION IN HEMATOLOGY

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Chemoimmunotherapy for Chronic Lymphocytic Leukemia

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Novel therapeutic targets in diffuse large B-cell lymphoma

(2013) Georg Lenz   EJC SUPPLEMENTS

Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance

(2013) Steve A Maxwell et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia

(2013) Wei Wu et al.   LEUKEMIA & LYMPHOMA

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

(2012) Joseph J. Buggy et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

CYLD Inhibits Tumorigenesis and Metastasis by Blocking JNK/AP1 Signaling at Multiple Levels

(2011) P. M. de Marval et al.   Cancer Prevention Research

Ubiquitin-mediated modulation of the cytoplasmic viral RNA sensor RIG-I

(2011) H. Oshiumi et al.   JOURNAL OF BIOCHEMISTRY

Chronicles of a death foretold: Dual sequential cell death checkpoints in TNF signaling

(2010) Marie Anne O’Donnell et al.   CELL CYCLE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ubiquitin chain cleavage: CYLD at work

(2010) Ramin Massoumi   TRENDS IN BIOCHEMICAL SCIENCES

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF- B

(2008) L. Yu et al.   BLOOD

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH